Month: August 2024

Contacts Robert Leininger Chair, Proxy Voting Committee (914) 921-7754 For further information please visit www.gabelli.com GAMCO Asset Management Inc. (“GAMCO”),...

Guelph, Ontario--(Newsfile Corp. - August 14, 2024) - Zentek Ltd.  (NASDAQ: ZTEK) (TSXV: ZEN) ("Zentek" or the "Company"), an intellectual...

Company Reieterates Gudience of 50% to 100% Revenue Growth in Fiscal 2025MINNEAPOLIS, MN, US, Aug. 14, 2024 (GLOBE NEWSWIRE) --...

Company Reieterates Gudience of 50% to 100% Revenue Growth in Fiscal 2025MINNEAPOLIS, MN, US, Aug. 14, 2024 (GLOBE NEWSWIRE) --...

Charlotte, North Carolina--(Newsfile Corp. - August 14, 2024) - cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBD-PA) one of the nation's...

Conference call to discuss financial and operational results scheduled for Thursday, August 15 at 8:30 a.m. U.S. Eastern Time HENDERSON,...

345% growth in Net Income and 62% improvement in Adjusted EBITDA compared to Q2 2023 ROUND ROCK, Texas, Aug. 14, 2024 (GLOBE...

NEPHRO CRRT study patient screening has initiated at multiple clinical sites The safety and effectiveness of nafamostat is being assessed...

GEORGE TOWN, Grand Cayman, Aug. 14, 2024 (GLOBE NEWSWIRE) -- StoneCo Ltd. (Nasdaq: STNE, B3: STOC31) (“Stone” or the “Company”)...

HORSHAM, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical...

VIENNA, Va.--(BUSINESS WIRE)--Spire Global, Inc. (NYSE: SPIR) (“Spire” or the “Company”) has filed a Form 12b-25, Notification of Late Filing,...

Lowest Adj. EBITDA Loss1 in Company History with 34.8% Year-over-Year ImprovementGross Margin of 27.4% Shows Expansion of ~10pts versus Prior...

Mooresville, N.C., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Strong Global Entertainment, Inc. (NYSE American: SGE) (the “Company” or “Strong Global...

- Preliminary data from the Phase 1 trial of PYX-201 remains on track to be announced in the fall of...

Presented Positive Interim ReSPECT-LM Phase 1 Data for Rhenium (186Re) Obisbemeda for Leptomeningeal MetastasesPresented Positive Topline Clinical Trial Results for...

– In June 2024, the Company announced groundbreaking pivotal study data for PRGN-2012 gene therapy at the 2024 ASCO annual...

WEST SACRAMENTO, Calif.--(BUSINESS WIRE)--Origin Materials, Inc. (“Origin,” “Origin Materials,” or the “Company”) (Nasdaq: ORGN, ORGNW), a technology company with a...

LOS ANGELES, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Nova LifeStyle, Inc. (NASDAQ: NVFY) (“Nova LifeStyle” or the “Company”) today announced its...

Prepares for September 17, 2024, Evie Ring back in stock dateAnnounces brand partnership with digital creator Heidi D'AmelioFocuses on launch...

– Primary focus continues to be on upcoming results from ENLIGHTEN 1 Phase 3 extension study in 4Q 2024 and...

Submitted New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for LNZ100 for the treatment of presbyopia...

SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW), a leading developer of non-invasive medical diagnostic technology, today reported financial results for...

WILSONVILLE, Ore.--(BUSINESS WIRE)--ESS Tech, Inc. (“ESS,” “ESS, Inc.” or the “Company”) (NYSE: GWH), a leading manufacturer of long-duration energy storage...

GTB-3650 TriKE® Phase 1 trial initiation expected in 2H 2024; initial clinical data expected in 1H 2025GTB-5550 TriKE® IND submission for treatment...

WESTLAKE VILLAGE, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced...

NANPING, China, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Golden Heaven Group Holdings Ltd. ("Golden Heaven" or the "Company") (Nasdaq: GDHG),...

Fort Lauderdale, Florida--(Newsfile Corp. - August 14, 2024) - Flora Growth Corp. (NASDAQ: FLGC) (FSE: 7301) ("Flora" or the "Company")...

- First patient treated in May for liver metastases from colorectal cancer - - Publication in June in Cancers journal...

Announced plan to initiate Phase 3 VIKTORIA-2 trial evaluating gedatolisib combined with fulvestrant plus a CDK4/6 inhibitor as first-line treatment...

Second quarter revenue increased to $13.0 million compared to $12.6 million for the second quarter of 2023.Half year revenue increased...

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of...

Clinical proof-of-concept monotherapy data for once daily, first-line firmonertinib in EGFR PACC mutant non-small cell lung cancer (NSCLC) to be...

14% Revenue and 8% Orders Growth in Q4; Company issues FY25 Guidance MADISON, Wis., Aug. 14, 2024 /PRNewswire/ -- Accuray...

Revenue increases 27% year over yearReports gain of $3.7 million from strategic acquisition of Rhode Island Radiation Therapy Cancer Centers...